Arrixaca (Hospital) participates in the first clinical trial promoted by the Ministry of Health to prevent coronavirus disease in health professionals
Allows assessing 4,000 health professionals for the risk of developing the disease
The Hospital of La Arrixaca de Murcia will participate in the first clinical trial aimed at preventing coronavirus disease in health professionals promoted by the Government of Spain, in which 4,000 specialists from 62 centres in thirteen autonomous communities will participate and which will be launched in the next days.
The Minister of Health, Salvador Illa, who announced it in the third Commission for Health and Consumer of the Congress, has stated that it is the largest study with these characteristics in Europe and one of the largest in the world, who will also participate in it, in addition to medical and nursing personnel, caretakers, pharmacists, radiology and laboratory technicians, which means a broad representation of all the professions that are acting against the virus in the hospital environment.
The objective of EPICOS, (Clinical Trial for the Prevention of Coronavirus Infection in Healthcare), which is expected to have the first results in four weeks, is to assess the probability of developing the symptoms of COVID-19 disease in healthcare personnel from high risk. To do this, one or two drugs will be administered preventively and randomly to be compared with a placebo group, in line with the guidelines of W.H.O. and the scientific community.
Thus, the preventive efficacy of three strategic treatments will be compared: hydroxychloroquine, anti-retrovirals that are used to treat HIV infection (emtricitabine/tenofovir disoproxil) and the combination of both. Preventive treatment will last 12 weeks, although monthly analysis will be carried out to evaluate the effectiveness of each option.
With this clinical trial, the Ministry of Health, through the National AIDS Plan and with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS), seeks to protect health professionals who are on the front line of the response to the pandemic, and to patients, to whom health personnel with asymptomatic disease may inadvertently transmit the disease.